Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 45.86 USD 0.72% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Protagonist Therapeutics Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Protagonist Therapeutics Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Other Equity
$1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Equity
-$2.3B
CAGR 3-Years
10%
CAGR 5-Years
2%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Other Equity
$18.4B
CAGR 3-Years
526%
CAGR 5-Years
175%
CAGR 10-Years
61%
Amgen Inc
NASDAQ:AMGN
Other Equity
-$336m
CAGR 3-Years
25%
CAGR 5-Years
6%
CAGR 10-Years
-12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Equity
-$22.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Equity
$60.2m
CAGR 3-Years
82%
CAGR 5-Years
29%
CAGR 10-Years
8%
No Stocks Found

Protagonist Therapeutics Inc
Glance View

Market Cap
2.7B USD
Industry
Biotechnology

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 118 full-time employees. The company went IPO on 2016-08-11. The firm uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s alpha-4-beta-7 (α4β7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted α4β7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.

PTGX Intrinsic Value
18.46 USD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Protagonist Therapeutics Inc's Other Equity?
Other Equity
1.3m USD

Based on the financial report for Sep 30, 2024, Protagonist Therapeutics Inc's Other Equity amounts to 1.3m USD.

Back to Top